Brought to you by 
Genome editing company Editas Medicine nets $101mm in IPO
20 Apr 2016
Executive Summary
Editas Medicine Inc. netted $101mm in its IPO of 6.8mm shares (including full exercise of the 885k overallotment option) at $16 per share. Proceeds will be used to fund the company's trials for LCA10 (Leber congenital amaurosis type 10; genetic progressive form of blindness), for preclinical studies with the candidate under its Juno Therapeutics collaboration (entered into in May 2015), and for expansion of platform technology.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
-
Drug Delivery
- Macromolecule
-
Drug Delivery
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
-
Drug Discovery Tools
- Genomics-Proteomics
Deal Status
- Final
Deal Type
-
Financing
- IPO
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Genome editing company Editas Medicine nets $101mm in IPO
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice